Precision Psychiatry
Starts Here
Bringing patient biology to the centre of psychiatric drug development.
Bringing patient biology to the centre
of psychiatric drug development.
About
MeOmics is creating a new way to discover psychiatric drugs by growing human brain cells from the patient population.
We measure advanced electrical activity and harness AI to understand how patient brain cells signal and how they respond to treatments. The goal is to make psychiatric medicine more precise and effective for each patient.
The Problem
Most psychiatric drugs fail in trials as they don’t reflect the diversity of real patients, and identifying the most suitable treatments can be a long process of trial and error.
Our Breakthrough
We grow human neurons from patients’ stem cells to map brain activity and generate biologically relevant data. With AI‑driven analysis, we predict which type of patients are most likely to respond to specific treatments before trials begin, enabling more precise drug‑development decisions.
Impact
Expertise
MeOmics™ is partnered up with
world-leading industry experts.
Collaborators and Partners
Accelerators and Programmes
Leadership Team
Dr Lucy Sykes
CEO
PhD in neuroscience with more than ten years’ biotech leadership experience leading cell and molecular biology-driven drug discovery.
Alasdair Pettigrew
COO
Technology expert with over 30 years-experience in scale-up & commercialisation.
Alicia Campbell
Head of Lab
Experienced Stem Cell expert for upscaling, advanced cell therapies and ISO accredited labs.
Board of Directors & Advisors:
Richard Bungay
Chairperson
Over 25 years’ experience in senior finance and strategic roles including at Imophoron, Mereo BioPharma, and Celltech. Currently COO at Sitala Bio and a Non-Executive Director of Cambridge Cognition.
Dr Mark Treherne
Strategic Advisor
Over 25 years in the biopharma industry, previously led neurodegeneration research at Pfizer. Helped to raise over £370M and out-licensed assets exceeding £1.5 billion. PhD in Pharmacology from the University of Cambridge.
Ben Sykes
Data Expert and Advisor
Senior software engineer, with previous leadership roles as architect for GE’s Digital Twin Platform. Over 20 years experience in technical architecture, driven by high quality engineering, while balancing fidelity and time-to-market.
Prof Jeremy Hall
Co-founder and Clinical Advisor
Professor of Integrative Neuropsychiatric cell biology and Director of Neuroscience and Mental Health Innovation Institute.
Prof Adrian Harwood
Co-founder and Technical Advisor
Professor of Integrative Neuropsychiatric cell biology and Director of Neuroscience and Mental Health Innovation Institute.
Prof James Walters
Co-founder and Technical Advisor
What if you could help cut psychiatric drug
trial failures before they start?
MeOmics – pioneers the forefront of precision psychiatry